CARIBOU BIOSCIENCES INC
CRBUNASDAQTrading Snapshot
- Day Range
- $1.26 – $1.28
- 52-Week Range
- $1.22 – $3.54
- Volume
- $5.04B
- Avg Volume
- $4.38B
- Shares Outstanding
- 99.2M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $1M
- P/E Ratio
- -1.1
- P/S Ratio
- 12.2x
- EPS (TTM)
- $-1.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.7%
Why Investors Own CRBU
- ✓High-growth profile — revenue up +19.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CARIBOU BIOSCIENCES INC
CRBU
StockOtter · stockotter.spaceAbout CARIBOU BIOSCIENCES INC
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revisin
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU
BlackRock Inc. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ: CRBU) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,815,
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75
Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. One investment ana
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers